After Northland Securities and Guggenheim gave Zogenix (NASDAQ: ZGNX) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Tim Lugo maintained a Buy rating on Zogenix yesterday. The company’s shares closed yesterday at $47.65.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 5.6% and a 38.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $60.13, implying a 26.2% upside from current levels. In a report released yesterday, Northland Securities also assigned a Buy rating to the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Based on Zogenix’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.2 million. In comparison, last year the company had a GAAP net loss of $30.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
